This prospective study evaluated the pharmacologic effect of oral acetazolamide on structural and functional outcomes in patients with X-linked retinoschisis (XLRS) using a cross-over design.
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiology practice — this is an ophthalmology/retinal study with no direct relevance to hearing, balance, or audiology clinical care.
While not directly relevant to audiology, this study's crossover design in a rare genetic sensory disorder offers a methodological template that could inform trial design in rare auditory genetic conditions.
- 01REAXIS is a prospective crossover study of oral acetazolamide in X-linked retinoschisis — a rare inherited retinal condition.
- 02The study evaluated structural outcomes (fluid pocket size) and functional outcomes (vision) with the drug.
- 03X-linked retinoschisis has no direct audiology connection; this article is outside the core audiology domain.
- 04Crossover design strengthens internal validity for this small, rare-disease population.
- 05Published in a specialist ophthalmology journal; no hearing or tinnitus outcomes reported.
Oral acetazolamide reduces cystoid fluid collections in patients with X-linked retinoschisis.
studypartially supported- PMID
- 42655987
- DOI
- 10.1080/13816810.2026.2720681.
- Journal
- Ophthalmic Genetics
- Publication type
- research_article
- Evidence level
- 1b
- Population
- Patients with X-linked retinoschisis and cystoid fluid collections
- Intervention
- Oral acetazolamide
- Comparator
- Crossover (no treatment / alternative period)
Primary outcomes
Change in cystoid fluid collection size (structural outcome); Change in visual function (functional outcome)